HK1206996A1 - Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3 - Google Patents

Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3

Info

Publication number: HK1206996A1
Authority: HK; Hong Kong
Prior art keywords: masp; 1masp; inhibting; compositions; treatment
Prior art date: 2012-04-06

Application number

HK15107717.0A

Other languages

English (en)

Chinese (zh)

Inventor

Hans-Wilhelm Schwaeble

Gregory A Demopulos

Original Assignee

Omeros Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-06

Filing date

2015-08-10

Publication date

2016-01-22

2015-08-10 Application filed by Omeros Corp filed Critical Omeros Corp

2016-01-22 Publication of HK1206996A1 publication Critical patent/HK1206996A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Mechanical Treatment Of Semiconductor (AREA)
Medicinal Preparation (AREA)

HK15107717.0A 2012-04-06 2015-08-10 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3 HK1206996A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261621461P	2012-04-06	2012-04-06
PCT/US2013/035488 WO2013180834A2 (en)	2012-04-06	2013-04-05	Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number	Publication Date
HK1206996A1 true HK1206996A1 (en)	2016-01-22

Family

ID=49325295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15107717.0A HK1206996A1 (en)	2012-04-06	2015-08-10	Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria masp-1masp-2 / masp-3

Country Status (29)

Country	Link
US (3)	US20130273053A1 (xx)
EP (2)	EP3366307B1 (xx)
JP (3)	JP6366571B2 (xx)
KR (2)	KR102318623B1 (xx)
CN (1)	CN104661676A (xx)
AU (3)	AU2013267909B2 (xx)
BR (1)	BR112014024793A2 (xx)
CA (2)	CA2869326C (xx)
CL (1)	CL2014002694A1 (xx)
CY (1)	CY1120736T1 (xx)
DK (2)	DK2833907T3 (xx)
ES (2)	ES2670668T3 (xx)
HK (1)	HK1206996A1 (xx)
HR (1)	HRP20180671T1 (xx)
HU (1)	HUE036930T2 (xx)
IL (2)	IL234991B (xx)
IN (1)	IN2014KN02324A (xx)
LT (1)	LT2833907T (xx)
MX (2)	MX357540B (xx)
NO (1)	NO2881536T3 (xx)
NZ (2)	NZ629675A (xx)
PL (2)	PL2833907T3 (xx)
PT (1)	PT2833907T (xx)
RS (1)	RS57266B1 (xx)
RU (2)	RU2018114903A (xx)
SI (1)	SI2833907T1 (xx)
TR (1)	TR201806939T4 (xx)
WO (1)	WO2013180834A2 (xx)
ZA (1)	ZA201408100B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME03755B (me) *	2011-05-04	2021-04-20	Omeros Corp	Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
BR112014031522A2 (pt) *	2012-06-18	2017-08-01	Omeros Corp	métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ729747A (en) *	2013-03-15	2020-03-27	Omeros Corp	Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
KR20230073346A (ko)	2016-11-28	2023-05-25	추가이 세이야쿠 가부시키가이샤	리간드 결합 활성을 조정 가능한 리간드 결합 분자
TW202323287A (zh)	2016-11-28	2023-06-16	日商中外製藥股份有限公司	包含抗原結合域與運送部分的多胜肽
EP3606965A4 (en) *	2017-04-03	2021-01-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MASP-1 ANTIBODIES AND METHODS OF USE
EP3719035A4 (en)	2017-11-28	2021-09-01	Chugai Seiyaku Kabushiki Kaisha	POLYPEPTIDE INCLUDING AN ANTIGEN BINDING DOMAIN AND A TRANSPORT SECTION
WO2019230867A1 (en)	2018-05-30	2019-12-05	Chugai Seiyaku Kabushiki Kaisha	Polypeptide comprising aggrecan binding domain and carrying moiety
MX2022001268A (es) *	2019-07-31	2022-02-22	Biocryst Pharm Inc	Regimenes de dosificacion para inhibidores orales del factor d del complemento.
EP4069238A1 (en)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2 inhibitors and methods of use
AU2020395306A1 (en)	2019-12-04	2022-06-30	Omeros Corporation	MASP-2 inhibitors and methods of use
AU2020398241A1 (en)	2019-12-04	2022-06-30	Omeros Corporation	MASP-2 inhibitors and methods of use
BR112023002843A2 (pt)	2020-08-18	2023-03-14	Omeros Corp	Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, molécula de ácido nucleico, vetor de clonagem ou cassete de expressão, célula, métodos para gerar um anticorpo isolado ou fragmento de ligação a antígeno do mesmo, para determinar a presença ou quantidade de fator d maduro e de pró-fator d em uma amostra de teste, para avaliar o grau de ativação do caminho alternativo de complemento (apc) em uma amostra de teste, para monitorar a eficácia de tratamento com um anticorpo inibidor de lectina serina protease 3 de ligação a manana ou fragmento de ligação a antígeno do mesmo e para tratar um sujeito mamífero sofrendo de ou em risco de desenvolver uma doença ou distúrbio do caminho alternativo, composição, substrato para o uso em um imunoensaio, kit para detectar a presença ou quantidade de fator d maduro em uma amostra de teste, composição farmacêutica, e, artigo de fabricação
CN114295594B (zh) *	2021-12-06	2023-09-19	贵州理工学院	一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
DE69030172T2 (de)	1990-01-26	1997-06-19	Immunomedics Inc	Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5837242A (en)	1992-12-04	1998-11-17	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US20030186419A1 (en) *	1999-12-02	2003-10-02	Jensenius Jens Christian	Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) *	2001-07-23	2006-05-09	Intel Corporation	Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
US7297348B2 (en)	2002-07-19	2007-11-20	Omeros Corporation	Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20060140939A1 (en) *	2003-02-21	2006-06-29	Fung Sek C M	Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20050169921A1 (en) *	2004-02-03	2005-08-04	Leonard Bell	Method of treating hemolytic disease
EP1713929A2 (en) *	2004-02-03	2006-10-25	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
US7803931B2 (en) *	2004-02-12	2010-09-28	Archemix Corp.	Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
RU2515108C2 (ru)	2005-08-19	2014-05-10	Эббви Инк	Иммуноглобулин с двойными вариабельными доменами и его применения
EP1885047B1 (en) *	2006-07-31	2008-12-31	C.R.F. Società Consortile per Azioni	Electric generator device actuated by a fluid flow
ES2628973T3 (es)	2007-05-31	2017-08-04	University Of Washington	Mutagénesis inducible de genes diana
KR20110047255A (ko) *	2008-09-26	2011-05-06	로슈 글리카트 아게	이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
AU2010203712A1 (en) *	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
US20120022543A1 (en) *	2009-03-05	2012-01-26	Smith & Nephew, Inc.	System, method, and apparatus for locating a femoral neck guide wire
CN102712687A (zh) *	2009-07-17	2012-10-03	丹麦国家医院	作为补体激活的抑制剂的masp同种型
EA201290286A1 (ru) *	2009-11-05	2013-01-30	Алексион Кембридж Корпорейшн	Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
KR101720562B1 (ko)	2011-04-08	2017-03-30	유니버시티 오브 레스터	Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법

2013
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/en active
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en active Application Filing
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending

Also Published As

Publication number	Publication date
JP6815355B2 (ja)	2021-01-20
CN104661676A (zh)	2015-05-27
IL274721A (en)	2020-07-30
ES2670668T3 (es)	2018-05-31
RU2018114903A (ru)	2019-03-04
RU2018114903A3 (xx)	2021-08-12
NZ629675A (en)	2017-02-24
CA3087933A1 (en)	2013-12-05
HUE036930T2 (hu)	2018-08-28
MX357540B (es)	2018-07-13
KR102318623B1 (ko)	2021-11-02
AU2013267909A1 (en)	2014-11-27
EP2833907A2 (en)	2015-02-11
JP2015514117A (ja)	2015-05-18
DK3366307T3 (da)	2021-11-01
IL234991B (en)	2020-06-30
EP3366307B1 (en)	2021-07-28
IL274721B (en)	2022-04-01
RU2014144621A (ru)	2016-05-27
DK2833907T3 (en)	2018-05-28
LT2833907T (lt)	2018-06-11
AU2018200721B2 (en)	2020-03-26
JP6366571B2 (ja)	2018-08-01
CA2869326C (en)	2021-09-21
MX2014012045A (es)	2015-05-15
TR201806939T4 (tr)	2018-06-21
PL3366307T3 (pl)	2022-03-07
ZA201408100B (en)	2022-05-25
PL2833907T3 (pl)	2018-08-31
NO2881536T3 (xx)	2018-06-30
US20190382505A1 (en)	2019-12-19
MX2018008658A (es)	2021-10-19
AU2013267909B2 (en)	2018-03-01
RU2655299C2 (ru)	2018-05-24
NZ781091A (en)	2022-04-29
EP2833907B1 (en)	2018-02-28
EP3366307A1 (en)	2018-08-29
IL234991A0 (en)	2014-12-31
CA2869326A1 (en)	2013-12-05
US20130273053A1 (en)	2013-10-17
ES2894944T3 (es)	2022-02-16
JP2021001199A (ja)	2021-01-07
NZ727063A (en)	2021-10-29
SI2833907T1 (en)	2018-07-31
AU2020204163A1 (en)	2020-07-09
JP2018162307A (ja)	2018-10-18
IN2014KN02324A (xx)	2015-05-01
KR102142508B1 (ko)	2020-08-10
PT2833907T (pt)	2018-05-29
KR20150003785A (ko)	2015-01-09
WO2013180834A3 (en)	2014-04-03
AU2018200721A1 (en)	2018-02-22
WO2013180834A2 (en)	2013-12-05
RS57266B1 (sr)	2018-08-31
CY1120736T1 (el)	2019-12-11
US20220242972A1 (en)	2022-08-04
EP2833907A4 (en)	2016-03-16
CL2014002694A1 (es)	2015-08-28
BR112014024793A2 (pt)	2019-08-27
HRP20180671T1 (hr)	2018-07-13
KR20200097808A (ko)	2020-08-19

Publication	Publication Date	Title
HRP20180671T1 (hr)	2018-07-13	Pripravci za i postupci inhibiranja masp-1 i/ili masp-3 u liječenju paroksizmalne noćne hemoglobinurije
IL266582A (en)	2019-07-31	Preparations and methods for the treatment of hemoglobin diseases
HK1209788A1 (en)	2016-04-08	Methods and compositions for the treatment of lysosomal storage diseases
HK1210957A1 (en)	2016-05-13	Effluz inhibitor compositions and methods of treatment using the same
EP2831001A4 (en)	2016-04-27	COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
EP2736528A4 (en)	2015-03-18	COMPOSITIONS AND METHODS OF TREATING HIV
HK1204988A1 (en)	2015-12-11	Methods and compositions for preventing or treating ophthalmic conditions
IL238177A0 (en)	2015-05-31	Methods and preparations for the treatment of cancer
ZA201408056B (en)	2016-04-28	Compositions and methods for the treatment of mucositis
ZA201408055B (en)	2016-03-30	Compositions and methods for the treatment of local pain
IL225793A0 (en)	2013-09-30	Methods and preparations for curing insulin-related medical conditions
HK1201045A1 (en)	2015-08-21	Compositions and methods for the diagnosis and treatment of tumor
HK1220374A1 (zh)	2017-05-05	用於治療碳氧血紅蛋白血症的組合物和方法
PL3082845T3 (pl)	2021-08-02	Sposoby i kompozycje do leczenia neuropatii obwodowych
EP2814491A4 (en)	2015-08-26	FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES
HK1216721A1 (zh)	2016-12-02	治療肝臟疾病或病狀的用途和方法
EP2800568A4 (en)	2015-06-10	COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
EP2547368A4 (en)	2014-08-06	METHOD AND COMPOSITIONS FOR CANCER TREATMENT
ZA201503844B (en)	2017-11-29	Compositions and methods for treating dental caries
ZA201408058B (en)	2016-03-30	Compositions and methods for the treatment of epilepsy
ZA201408065B (en)	2016-04-28	Compositions and methods for the treatment of diabetes
HK1206598A1 (en)	2016-01-15	Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof
PT2862576T (pt)	2017-03-16	Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite